Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Assets (2016 - 2025)

Vanda Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $141.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 34.8% year-over-year to $141.7 million; the TTM value through Dec 2025 reached $829.2 million, down 3.08%, while the annual FY2025 figure was $141.7 million, 34.8% down from the prior year.
  • Non-Current Assets for Q4 2025 was $141.7 million at Vanda Pharmaceuticals, down from $233.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $233.6 million in Q3 2025 and bottomed at $105.0 million in Q3 2023.
  • The 5-year median for Non-Current Assets is $121.5 million (2021), against an average of $157.7 million.
  • The largest annual shift saw Non-Current Assets soared 102.53% in 2024 before it plummeted 34.8% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $115.5 million in 2021, then decreased by 0.46% to $115.0 million in 2022, then surged by 87.46% to $215.5 million in 2023, then rose by 0.84% to $217.3 million in 2024, then tumbled by 34.8% to $141.7 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Non-Current Assets are $141.7 million (Q4 2025), $233.6 million (Q3 2025), and $229.8 million (Q2 2025).